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Study of mirtazapine for agitated behaviours in dementia 
(SYMBAD): a randomised, double-blind, placebo-controlled 
trial
Sube Banerjee, Juliet High, Susan Stirling, Lee Shepstone, Ann Marie Swart, Tanya Telling, Catherine Henderson, Clive Ballard, Peter Bentham, 
Alistair Burns, Nicolas Farina, Chris Fox, Paul Francis, Robert Howard, Martin Knapp, Iracema Leroi, Gill Livingston, Ramin Nilforooshan, 
Shirley Nurock, John O’Brien, Annabel Price, Alan J Thomas, Naji Tabet
Summary
Background Agitation is common in people with dementia and negatively affects the quality of life of both people with 
dementia and carers. Non-drug patient-centred care is the first-line treatment, but there is a need for other treatment 
when this care is not effective. Current evidence is sparse on safer and effective alternatives to antipsychotics. We 
assessed the efficacy and safety of mirtazapine, an antidepressant prescribed for agitation in dementia.
Methods This parallel-group, double-blind, placebo-controlled trial—the Study of Mirtazapine for Agitated Behaviours 
in Dementia trial (SYMBAD)—was done in 26 UK centres. Participants had probable or possible Alzheimer’s disease, 
agitation unresponsive to non-drug treatment, and a Cohen-Mansfield Agitation Inventory (CMAI) score of 45 or 
more. They were randomly assigned (1:1) to receive either mirtazapine (titrated to 45 mg) or placebo. The primary 
outcome was reduction in CMAI score at 12 weeks.  This trial is registered with ClinicalTrials.gov, NCT03031184, and 
ISRCTN17411897.
Findings Between Jan 26, 2017, and March 6, 2020, 204 participants were recruited and randomised. Mean CMAI 
scores at 12 weeks were not significantly different between participants receiving mirtazapine and participants 
receiving placebo (adjusted mean difference –1·74, 95% CI –7·17 to 3·69; p=0·53). The number of controls with 
adverse events (65 [64%] of 102 controls) was similar to that in the mirtazapine group (67 [66%] of 102 participants 
receiving mirtazapine). However, there were more deaths in the mirtazapine group (n=7) by week 16 than in the 
control group (n=1), with post-hoc analysis suggesting this difference was of marginal statistical significance 
(p=0·065).
Interpretation This trial found no benefit of mirtazapine compared with placebo, and we observed a potentially higher 
mortality with use of mirtazapine. The data from this study do not support using mirtazapine as a treatment for 
agitation in dementia.
Funding UK National Institute for Health Research Health Technology Assessment Programme.
Copyright © 2021 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY-NC-ND 
4.0 license.
Introduction 
Dementia is one of the most common and serious public 
health issues of our time.1 Over 46 million people have 
dementia worldwide, a figure set to double in the next 
20 years.2 The most common cause of dementia 
is Alzheimer’s disease; Alzheimer’s disease causes 
irreversible and progressive decline in memory, 
reasoning, communication skills, and the ability to 
undertake daily activities. Alongside this cognitive and 
functional decline, individuals may develop neuro­
psychiatric symptoms, such as agitation, sleep 
disturbance, depression, and psychosis.3 These symptoms 
are common, occurring in up to 90% of people with 
dementia, with agitation being one of the most persistent 
symptoms.4 Agitation is defined as inappropriate verbal, 
vocal, or motor activity that is not thought to be caused by 
an unmet need; it encompasses physical and verbal 
aggression and is particularly problematic.5 It affects 
nearly half of people with Alzheimer’s disease over a 
month,6 and 80% of those with clinically significant 
symptoms still have them 6 months later.7 Agitation is 
associated with deteriorating relationships with family 
and professional carers, care home admission, increased 
costs of care, carer burden and burnout, and decreased 
quality of life.5,7,8
Agitation in dementia is therefore a legitimate target 
for therapeutic intervention, but it has a number of 
possible causes, including pain, physical or 
psychological distress, misperception of threat (for 
example during personal care), and response to 
hallucinations or delusions. Use of non­pharmacological 
interventions that investigate cause and provide a 
tailored response as a first­line treatment for agitation 
in dementia, such as the DICE approach (Describe the 
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problem, Investigate the cause, Create a plan, Evaluate 
its effectiveness), is recommended as best practice.1,9 
However, given the clinical significance of agitation, 
there is a need for second­line treatments when no 
underlying causes are found or when correction of these 
causes has not resulted in improvement. The mainstay 
of drug treatment is antipsychotic medication. These 
drugs, however, have low efficacy, with the American 
Psychiatric Association guideline group reporting they 
“demonstrate minimal or no efficacy with strong 
placebo effects”.10 They also cause particular harms in 
those with dementia, including excess dementia­specific 
mortality. In the UK in 2009, there were an estimated 
1800 deaths and 1620 cerebrovascular adverse events 
attributable to the use of antipsychotics in dementia.11 
Although their rate of prescription to people with 
dementia has decreased,12 they are still commonly used; 
such treatment is largely unlicensed. In most countries, 
few or no treatments have regulatory approval for such 
use. In the UK, the only drugs with a relevant licence 
are risperidone and haloperidol and these are highly 
restrictive. Risperidone is indicated for “short­term 
treatment (up to six weeks) of persistent aggression in 
patients with moderate to severe Alzheimer’s dementia 
unresponsive to non­pharmacological approaches and 
when there is a risk of harm to self or others” and 
haloperidol for “persistent aggression and psychotic 
symptoms in moderate to severe Alzheimer’s dementia 
and vascular dementia [when non­pharmacological 
treatment is ineffective and there is a risk of harm to 
self or others]”.
Other drug treatments considered for agitation in 
dementia, such as the acetylcholinesterase inhibitor 
donepezil13 and the NMDA receptor inhibitor 
memantine,14 have been tested in randomised controlled 
trials and did not show efficacy. In a large multicentre 
trial, the anticonvulsant sodium valproate did not delay 
or prevent neuropsychiatric symptoms in dementia.15 
Benzodiazepines are used short­term clinically, but 
there are no trials, and adverse effects such as falls are 
common and of concern.16 Antidepressants have also 
been investigated as an alternative to antipsychotics. The 
CitAD trial of citalopram for agitated behaviours 
provided evidence that a target dose of 30 mg citalopram 
per day had a small positive effect on agitation in 
dementia17 in those who were less agitated and less 
cognitively impaired.18 Adverse cardiac and cognitive 
effects identified in the trial limit its clinical use. 
Antidepressants are not mentioned as a potential 
treatment for agitation in the English National Institute 
for Health and Care Excellence (NICE) guideline on 
dementia assessment and management,19 but they are 
increasingly used to treat agitation in dementia. This 
substitution strategy to avoid antipsychotic prescription 
was reported in a large US nursing homes study, which 
showed that mood stabilisers such as sodium valproate, 
Research in context
Evidence before this study
We searched PubMed and the Cochrane Library databases from 
inception up to Feb 19, 2021, using the terms “(dement* OR 
Alzheimer)” and “(agitat* OR aggress*)” and “(RCT OR 
random*)”. Only studies that had a pharmacological treatment 
arm and an outcome measure of agitation or aggression in 
people with dementia were included. Studies were required to be 
randomised controlled trials, or reviews and systematic reviews 
that reported the results of these trials. There were no language 
restrictions. A systematic review investigating pharmacological 
treatments of agitation in people with dementia included 
36 randomised controlled trials (5585 participants). 
A combination of dextromethorphan and quinidine (odds 
ratio 3·04, 95% CI 1·63–5·66), risperidone (1·96, 1·49–2·59), and 
selective serotonin reuptake inhibitor antidepressants 
(SSRIs; 1·61, 1·02–2·53) were found to be more efficacious than 
placebo. However, both antipsychotics and SSRIs are associated 
with serious potential harms and the data for the combination of 
dextromethorphan and quinidine were derived from a single 
study. Subsequently, a single paper describing two trials of the 
atypical antipsychotic brexpiprazole has reported mixed results.
Added value of this study
This current study shows that the noradrenergic and specific 
serotonergic antidepressant mirtazapine, one of the most 
widely prescribed antidepressants for older people, is no more 
effective than placebo in the treatment of agitation in 
dementia. The observation of potentially higher mortality in 
the group receiving mirtazapine than the group receiving 
placebo, although not definitive, provides further reason for 
caution in its use for this indication.
Implications of all the available evidence
The first line of management for agitation in dementia is a full 
assessment to identify if there is a modifiable cause for the 
behaviour. In all but the most urgent of situations, the next 
line is non-pharmacological treatment because such 
approaches have been shown to be at least as effective as drug 
treatment. Data from this study support the active monitoring 
of agitation in dementia without the prescription of 
medication as recommended in guidelines for depression. 
Antipsychotics and SSRIs are associated with substantial 
harms when used for the treatment of agitation in dementia. 
This study suggests that substituting the sedative 
antidepressant mirtazapine to avoid such harms is not a 
clinically effective strategy.
For the risperidone NICE 
guidelines see https://bnf.nice.
org.uk/drug/risperidone.html
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carbamazepine, and particularly gabapentin prescription 
rates increased as antipsychotics decreased.20,21 Such 
prescribing of antidepressants is part of the common 
polypharmacy seen in people with dementia in the 
community.22
Mirtazapine, a noradrenergic and specific serotonergic 
antidepressant, is widely used in older people; from 2009 
to 2014, in a study of 4·8 million antidepressant 
initiations in Europe, it was the antidepressant most 
commonly prescribed for older people and those with 
dementia.23 We examined it as a treatment for depression 
in dementia in the HTA­SADD trial and found no 
evidence of efficacy for depression.24 However, in 
secondary analyses of this population defined with a 
depressive illness and probable or possible Alzheimer’s 
dementia, we noted a possible positive effect of 
mirtazapine on neuropsychiatric symptoms (neuro­
psychiatric inventory [NPI] score at 13 weeks). For those 
with above median raw NPI scores, there was a 7·1 point 
difference in NPI score (95% CI –0·50 to 14·68; p=0·067) 
between mirtazapine and placebo, and a 13·2 point 
difference between mirtazapine and sertraline 
(4·47 to 21·95; p=0·003).25 Mirtazapine is a centrally 
active presynaptic α2­antagonist, increasing central 
noradrenergic and serotonergic neurotransmission via 
5­HT1 receptors, and the histamine H1­antagonistic 
activity of mirtazapine is associated with sedative 
properties, suggesting possible mechanisms for action in 
neuropsychiatric symptoms. It has less anticholinergic 
activity than many other antidepressants; unlike 
citalopram, and at therapeutic doses, it has been reported 
to have minimal effects on the cardiovascular system, 
suggesting it might not have the safety concerns 
associated with other drugs.
In this study, we aimed to establish the clinical 
effectiveness and safety profile of mirtazapine in 
reducing agitation in Alzheimer’s disease relative to 
placebo.
Methods 
Study design and participants 
We did a multicentre, parallel­group, double­blind, 
placebo­controlled, randomised trial of participants 
recruited from 26 UK National Health Service clinical 
centres with 6­week and 12­week follow­ups, using the 
12­week data for the primary outcome. Assessments 
were done in person by research workers in participants’ 
own homes or other agreed settings, except for the last 
individuals who were followed up during the COVID­19 
lockdown and thus assessed by telephone. Inclusion 
criteria mirrored clinical practice. Eligible partici­
pants met National Institute of Neurological and 
Communicative Diseases and Stroke—Alzheimer’s 
Disease and Related Disorders Association criteria for 
probable or possible Alzheimer’s disease26 (ascertained 
by referring psychiatrists) and coexisting agitation 
defined as a Cohen­Mansfield Agitation Inventory27 
(CMAI) score of 45 or more. The CMAI score was chosen 
in our study because it is the most commonly used 
instrument in trials for agitation in dementia, with 
robust psychometric properties including responsiveness 
to change. We also required evidence that the aetiology 
of agitated behaviours had been investigated and 
not responded to non­pharmacological management 
according to the Alzheimer’s Society and Department of 
Health algorithm.28 Participants were ineligible for 
inclusion if they were considered clinically too critically 
unwell for participation (eg, suicide risk), had absolute 
contraindications to trial drugs (hypersensitivity to 
mirtazapine, hypersensitivity to carbamazepine or 
structurally related drugs, second­degree atrioventricular 
block, use of monoamine oxidase inhibitors, or a history 
of bone marrow depression or hepatic porphyria), were 
already taking antidepressants or antipsychotics, were in 
another Investigational Medicinal Product trial, were 
women under the age of 55 of childbearing potential, 
or had no family or professional carer informant 
available. Ethics approval was obtained from the 
Hampshire A South Central Research Ethics Committee 
(15/SC/0606) and the Medicines and Healthcare products 
Regulatory Agency. The study received local NHS Trust 
approvals, and written consent or assent (with legal 
representative consent) was obtained from all participants 
(for more details see trial protocol, section 5.3.6, in the 
appendix p 3).
Randomisation and masking 
After baseline assessment and consent, participants 
were randomly allocated (1:1) to receive either placebo 
or mirtazapine, together with treatment as usual. 
Random allocation was block stratified by centre and 
type of residence (care home vs own household) with 
random block lengths of two or four. The Norwich 
Clinical Trials Unit generated the randomisation 
sequence using ASP.net software. The trial was double­
blind, with drug and placebo identically encapsulated. 
Referring clinicians, participants, the trial management 
team, and the research workers completing baseline 
and follow­up assessments were masked to group 
allocation.
Procedures 
The target dose was 45 mg per day for mirtazapine. 
Participants could take up to three capsules orally once a 
day (up to three doses of mirtazapine 15 mg or matched 
placebo). Participants started on one capsule, increasing 
the dose to two capsules at 2 weeks, and three capsules at 
4 weeks. The research worker telephoned carers at 
weeks 2 and 4 and completed questionnaires concerning 
adverse effects and adherence. Participants with dose­
limiting issues, such as side­effects, either remained on 
the current dose or stopped the study drug. The 
remaining participants moved to the next dose level. 
Thereafter, clinicians were free to adjust the dose.
See Online for appendix
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Outcomes 
The primary outcome was clinical effectiveness of 
mirtazapine in terms of reduction of agitation, measured 
by CMAI score at 12 weeks. Secondary outcomes were: 
CMAI score at 6 weeks, disease­specific health­related 
quality of life (DEMQOL and DEMQOL­proxy), generic 
health­related quality of life (EQ­5D­5L assessed by the 
carer for the participant and themselves), neuropsychiatric 
symptoms (NPI), carer mental health (12­item General 
Health Questionnaire), carer burden (Zarit Carer Burden 
Inventory), and cognition (standardised mini­mental 
state examination; for references see appendix p 2). 
Safety outcomes were death, withdrawal, drug adherence, 
adverse events, and Columbia Suicide Severity Rating 
Scale score. The cost­effectiveness of the intervention, 
using data collected with the Client Service Receipt 
Inventory, will be reported elsewhere. All outcomes were 
assessed at 6 and 12 weeks by a home visit completed by 
a study research worker until the COVID­19 lockdown 
when they were completed by telephone. Adverse events 
were recorded up to 4 weeks after the last dose of 
medication. Percentage compliance was estimated as the 
proportion of tablets taken compared with number of 
tablets returned at 6­week or 12­week visits. Carer 
telephone interviews including the CMAI were 
completed at 26 and 52 weeks and these long­term 
follow­up data will be reported elsewhere.
Protocol changes 
SYMBAD was designed as a three­arm trial, including 
carbamazepine, mirtazapine, and placebo groups with 
randomisation on a 1:1:1 basis. Due to slower than 
projected recruitment, the trial protocol was reviewed 
with the funder and through consultation with the Data 
Monitoring Committee and Trial Steering Group. The 
Data Monitoring Committee considered efficacy data 
(the primary endpoint, CMAI at 12 weeks), safety data 
(frequency of adverse events and serious adverse events 
on an individual basis), and treatment compliance 
(dropouts and compliance with the prescribed amount of 
treatment medication). This consideration was done 
blind to subgroup but with knowledge of placebo group 
identity. The Data Monitoring Committee recommended 
discontinuation of the carbamazepine group on the basis 
of efficacy and safety data. The carbamazepine group 
was closed in August, 2018, after 40 people had been 
randomly allocated to the group. The data from this 
group are not reported here but will be presented in our 
final funder report, which will be published as a UK 
National Institute for Health Research­Health Technology 
Assessment monograph.
Statistical analysis 
We aimed for an overall sample of 222 participants 
(randomly allocated 1:1) to provide 80% power using 
two­sided 5% significance tests to detect a drug versus 
placebo mean difference in CMAI scores of six points at 
Figure 1: Trial profile
CMAI=Cohen Mansfield Agitation Inventory. *Reasons for ineligibility: one no diagnosis of probable or possible 
Alzheimer’s disease; one no diagnosis of coexisting agitated behaviour; one no evidence that behaviour does not 
respond to management according to Alzheimer’s Society and Department of Health algorithm; 15 no assessment 
of CMAI score of 45 or greater; one no written informed consent to enter and be randomised into the trial; 
one current treatment with antidepressant (including monoamine oxidase inhibitors), anticonvulsants, or 
antipsychotics; two case too critical for randomisation; 12 other or unknown reasons (following text taken from 
text entries: one psychiatrist decided to proceed with an alternative medication; one patient admitted to hospital 
and no longer appropriate; one patient not eligible: completed no further assessments after CMAI; six patients 
ineligible; one patient scored less than 45 on CMAI; one started memantine which reduced agitation; one not 
randomised as behaviour settled and did not require medication). †One abnormal blood results, one patient, carer, 
or legal representative withdrew consent. ‡One non-compliance and general practitioner prescription of 
mirtazapine, one too agitated to continue, one transient ischaemic attack. §One deteriorating health and 
readmission to hospital. ¶One local Principal Investigator determined that it was no longer in patient’s best 
interests, one compliance problems due to participant and carer capability and ill health.  
102 assigned mirtazapine
87 followed up at week 6 
81 followed up at week 12; 








1 duplicate randomisation       
2 ineligible due to medication       
87 excluded
11 did not consent to participate
34 ineligible or eligibility not determined*
2 not randomised†
40 randomly assigned to carbamazepine
443 excluded
  429 did not agree to home visit
    14 agreed to home visit but home visit 
did not take place
6 discontinued treatment
2 patient died
1 patient, carer, or legal 
representative withdrew consent




294 had a home visit to confirm eligibility
737 participants assessed for eligibility
95 followed up at week 6 
90 followed up at week 12; 
CMAI data of 87 participants 
analysed
7 discontinued treatment
5 patient, carer, or legal 
representative withdrew consent 




3 patient, carer, or legal 
representative  withdrew consent
1 lost to follow-up
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12­week follow­up, assuming attrition of less than 10%. 
Assuming a common standard deviation of 15 points, 
this equates to a Cohen’s effect size of 0·4 or a 
30% decrease in CMAI from placebo to active drug, both 
of which we defined as clinically significant.
The Data Monitoring Committee and the Trial Steering 
Group finalised and approved the statistical analysis plan. 
Statistical significance was set at a two­sided 5% for all 
analyses. Analyses were based on intention to treat (all 
participants were analysed according to the group to 
which they were randomly allocated, irrespective of the 
treatment or dose received). The primary outcome (CMAI 
at 12 weeks) was analysed using a general linear 
regression model including baseline CMAI score as a 
covariate, place of residence as a fixed effect, and 
recruitment centre as a random effect. Treatment group 
was added as a fixed effect, with two levels (placebo vs 
mirtazapine). Model assumptions were checked by use of 
diagnostic plots. The primary analysis used complete 
cases (excluding participants with missing values). 
Imputation was done under the missing at random 
assumption. A sensitivity analysis imputed missing 
values using multiple imputation with chained equations 
approach (the mi impute chained command in Stata). 
The analyses of secondary outcomes followed an 
analogous approach using general linear regression 
models including baseline outcome, stratification 
variables, and treatment group. We completed a post­hoc 
analysis comparing death rates in the groups using 
Fisher’s exact test. All analyses were completed with Stata 
version 16.1. This study is registered with ClinicalTrials.gov, 
NCT03031184, and ISRCTN17411897.
Role of the funding source 
The funder (UK National Institute for Health Research) 
and the sponsor (University of Sussex) had no role in 
study design, data collection, data analysis, data 
interpretation, or writing of the report.
Results 
We recruited participants between Jan 26, 2017, and 
Feb 6, 2020, and completed follow­up interviews by 
June 1, 2020. 737 participants were assessed for eligibility; 
after 533 participants were excluded, we randomly 
allocated 204 participants to the two groups, so that we 
had 102 participants in the mirtazapine group and 
102 participants in the placebo group (figure 1). 
79 participants of the mirtazapine group and 
87 participants of the control group (present at the 
12­week follow­up) were included in the primary 
analyses.
Table 1 shows baseline demographic and clinical 
characteristics of participants and carers. Groups were 
similar at baseline except for more female participants 
randomly allocated to receive mirtazapine (76 [75%] 
of 102 participants) than placebo (59 [58%] of 
102 participants). In light of this difference, sex was 
Mirtazapine group (n=102) Placebo group (n=102)
Participants
Age (SD) 82·2 (7·8) 82·8 (7·7)
Sex 102 102
Female 76 (75%) 59 (58%)
Male 26 (25%) 43 (42%)
Residence 102 102
Own household 55 (54%) 57 (56%)
Care home 47 (46%) 45 (44%)
Agitation: CMAI score (29–203) 102 (100%); 71·1 (16·4) 102 (100%); 69·8 (17·1)
Cognition: standardised MMSE score (0–30) 52; 13·4 (8·1) 50; 16·1 (6·7)
Condition-specific quality of life: DEMQOL 
score (28–122)
41; 92·4 (10·8) 37; 95·8 (10·2)
DEMQOL-proxy score (31–124) 100; 92·3 (15·0) 99; 90·9 (14·4)
Generic quality of life: EQ-5D score (proxy 
report by carer, 0–1)
100; 0·46 (0·34) 101; 0·50 (0·32)
Neuropsychiatric symptoms .. ..
NPI total score (0–144) 98; 32·7 (16·7) 102 (100%); 34·9 (18·2)
NPI agitation or aggression subscore 
(0–12)
99; 5·6 (3·2) 102 (100%); 5·6 (3·4)
NPI depression or anxiety or irritability 
subscore (0–36)
99; 9·9 (6·2) 102 (100%); 10·5 (7·0)
Suicidality: CSSRS 102 102
Suicidal ideation (lifetime) 18 (18%) 13 (13%)
Suicidal ideation (past month) 11 (11%) 11 (11%)
Suicidal behaviour (lifetime) 4 (4%) 0
Suicidal behaviour (past 3 months) 2 (2%) 0
Carers
Paid carers 39 (38%) 31 (30%)
Family carers 63 (62%) 71 (70%)
Family carer relationship
Partner or spouse 34 (54%) 35 (49%)
Son or daughter 21 (33%) 31 (44%)
Sibling 1 (2%) 0
Other relative 5 (8%) 3 (4%)
Friend 1 (2%) 2 (3%) 
Other 1 (2%) 0
Family carer occupation (preretirement)
Professional 13 (21%) 13 (18%)
Managerial and technical 23 (37%) 22 (31%)
Skilled non-manual 9 (14%) 11 (15%)
Skilled manual 11 (17%) 8 (11%)
Partly skilled 2 (3%) 8 (11%)
Unskilled 3 (5%) 0
Unemployed or unwaged 2 (3%) 5 (7%)
Unanswered 0 4 (6%)
Carer mental health (family carers only): 
GHQ-12
61; 15·0 (5·8) 66; 14·5 (4·9)
Carer burden: Zarit Carer Burden Inventory* 58; 33·8 (15·7) 66; 34·1 (13·9)
Carer generic quality of life: EQ-5D* 61; 0·79 (0·21) 66; 0·81 (0·22)
NPI carer distress subscore (0–60) 94; 14·1 (8·6) 99; 15·5 (9·0)
Data are n, n (%), mean (SD), or n (%); mean (SD). CMAI=Cohen Mansfield Agitation Inventory. CSSRS=Columbia Suicide 
Severity Rating Scale. DEMQOL=disease-specific health-related quality of life. GHQ-12=12-item General Health 
Questionnaire. MMSE=mini-mental state examination. NPI=neuropsychiatric inventory. *Only asked of family carers.  
Table 1: Baseline demographics and clinical characteristics of participants and carers
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included in an additional model as a sensitivity analysis. 
By week 12, similar numbers remained in the mirtazapine 
(80 [78%] of 102 participants) and the placebo group 
(89 [87%] of 102 participants).
Severity of agitation decreased in both groups at 
6 weeks by around 10 CMAI points and continued to be 
lower than baseline scores at 12 weeks (figure 2); this 
change between baseline and 6­week and 12­week 
outcomes is illustrated by the separation in 
95% confidence limits. At no point was the unadjusted or 
adjusted CMAI difference between the groups statistically 
significant (table 2). Table 2 presents the results from the 
general linear mixed modelling for the primary outcome. 
There was no evidence that mirtazapine improved 
agitation relative to placebo. The estimated adjusted 
effect on the CMAI was –1·74 (95% CI –7·17 to 3·69; 
p=0·530). This finding changed little with the addition of 
sex into the model. Table 2 shows the effect of mirtazapine 
compared with placebo on secondary outcomes in 
participants and table 3 shows this effect in carers. Again, 
there was no evidence of difference between the groups, 
apart from: a single significant difference in the Zarit 
Carer Burden Inventory at 12 weeks, which indicated 
Figure 2: Unadjusted mean CMAI scores (95% CI) by treatment group
Please note that the y-axis does not start at 0 in this figure. CMAI=Cohen 
Mansfield Agitation Inventory.






















Adjusted mean difference 
(95% CI)*
p value
n Mean (SD) n Mean (SD)
12-week primary outcome
Agitation: CMAI 79 61·4 (22·6) 87 60·8 (21·8) 0·59 (–6·22 to 7·40) –1·74 (–7·17 to 3·69)*;  
–0·93 (–6·42 to 4·56)†
0·530; 0·739
6-week secondary outcomes
Agitation: CMAI 84 61·4 (23·5) 88 60·0 (19·9) 1·39 (–5·15 to 7·93) –0·55 (–6·18 to 5·08) 0·848
Cognition: standardised MMSE 33 15·5 (7·1) 31 16·2 (7·2) –0·68 (–4·25 to 2·89) –0·14 (–1·17 to 1·45) 0·836
Quality of life: DEMQOL 32 95·1 (10·2) 32 96·8 (8·4) –1·69 (–6·38 to 3·00) 1·12 (–2·74 to 4·97) 0·570
Quality of life: DEMQOL-proxy 79 96·6 (14·7) 86 94·6 (16·2) 2·03 (–2·74 to 6·79) 0·80 (–3·18 to 4·77) 0·694
Quality of life: EQ-5D, proxy report 
by carer
82 0·48 (0·33) 87 0·56 (0·30) –0·08 (–0·17 to 0·02) –0·07 (–0·13 to 0·00) 0·061
Neuropsychiatric symptoms: NPI 
total score
84 27·1 (20·0) 88 24·8 (20·0) 2·29 (–3·73 to 8·31) 2·03 (–2·89 to 6·95) 0·419
Neuropsychiatric symptoms: NPI 
agitation and aggression subscore
84 4·0 (3·6) 88 4·2 (3·5) –0·20 (–1·28 to 0·87) –0·34 (–1·30 to 0·62) 0·490
Neuropsychiatric symptoms: NPI 
depression, anxiety, and irritability 
subscore
84 7·9 (7·7) 88 7·2 (8·2) 0·68 (–1·72 to 3·07) 0·70 (–1·24 to 2·63) 0·482
12-week secondary outcomes
Cognition: standardised MMSE 23 18·0 (6·0) 27 15·6 (7·5) 2·44 (–1·48 to 6·37) 1·45 (–0·20 to 3·10) 0·084
Quality of life: DEMQOL 24 94·3 (7·1) 24 97·1 (8·4) –2·83 (–7·35 to 1·68) –1·36 (–5·82 to 3·10) 0·549
Quality of life: DEMQOL-proxy 71 98·4 (14·5) 82 97·5 (12·4) 0·93 (–3·37 to 5·23) 0·44 (–3·09 to 3·96) 0·809
Quality of life: EQ-5D, proxy report 
by carer
77 0·46 (0·35) 84 0·50 (0·33) –0·04 (–0·14 to 0·07) –0·01 (–0·08 to 0·07) 0·822
Neuropsychiatric symptoms: NPI 
total score
75 23·9 (17·8) 84 25·7 (19·6) –1·80 (–7·69 to 4·09) –2·02 (–6·67 to 2·62) 0·393
Neuropsychiatric symptoms: NPI 
agitation and aggression subscore
76 4·1 (3·4) 84 4·5 (3·6) –0·40 (–1·49 to 0·70) –0·52 (–1·52 to 0·47) 0·305
Neuropsychiatric symptoms: NPI 
depression, anxiety, and irritability 
subscore
75 6·9 (6·7) 84 7·3 (8·0) –0·44 (–2·77 to 1·88) –0·58 (–2·43 to 1·27) 0·541
CMAI=Cohen Mansfield Agitation Inventory. DEMQOL=disease-specific health-related quality of life. EQ-5D=EuroQOL 5 dimension. MMSE=mini-mental state examination. 
NPI=neuropsychiatric inventory.  *Adjusted for prespecified factors: baseline CMAI, household status, and centre. †Adjusted for sex and prespecified factors: baseline CMAI, 
household status, and centre. 
Table 2: Comparisons of participant primary outcomes at 12 weeks and secondary outcomes at 6 weeks and 12 weeks
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higher carer burden in the mirtazapine group (adjusted 
difference 5·01 points, 95% CI 0·80 to 9·23; p=0·020); 
weaker evidence at 6 weeks (3·76, –0·03 to 7·83; 
p=0·069) in the same variable; and a weak association 
with higher proxy­rated EQ­5D quality of life in the 
placebo group at 6 weeks (–0·07, –0·13 to 0·00; p=0·061) 
that was not maintained at 12 weeks (–0·01, –0·08 to 0·07; 
p=0·822).
The mean overall dosage (including participants who 
withdrew from medication) was 30·5 mg per day for 
mirtazapine and compliance with study medication did 
not differ between groups (table 4). The use of permitted 
so­called rescue medication (lorazepam 0·5 mg or 
risperidone 0·5–1 mg) was similar in both groups with 
ten doses prescribed to nine individuals in the 
mirtazapine group and 18 doses to nine individuals in 
the placebo group.
Adverse events and severe adverse events were 
ascertained to 16 weeks or 4 weeks after last dose of 
investigational medical product; deaths were recorded up 
to 16 weeks after randomisation. Examining adverse 
events by week 16, there were 192 adverse events in 
102 participants in the placebo group, with 65 (64%) 
individuals having at least one adverse event, compared 
with 225 adverse events in 102 participants in the 
mirtazapine group, with 67 (66%) participants having at 
least one adverse event. There were 35 serious adverse 
events in 18 individuals in the placebo group, compared 
with 13 in eight individuals in the mirtazapine group. 
The systems affected by adverse events and severe 
adverse events by intervention group are presented in the 
appendix (p 1). Mortality differed between groups with a 
potentially higher rate in the mirtazapine group 
(seven deaths in the mirtazapine and one in the placebo 
group by 16­week safety follow­up). Post­hoc statistical 
analyses suggested weak evidence of a mortality 
difference between groups (Fisher’s exact test p=0·065). 










n Mean (SD) n Mean (SD)
6-week outcomes
Carer GHQ-12 50 12·8 (6·2) 54 12·1 (4·9) 0·69 (–1·46 to 2·85) 0·61 (–1·21 to 2·42) 0·512
Carer EQ-5D 50 0·83 (0·16) 55 0·83 (0·15) 0·00 (–0·06 to 0·06) 0·01 (–0·04 to 0·05) 0·821
Zarit Carer Burden Inventory 46 34·7 (16·3) 49 29·4 (13·9) 5·35 (0·82 to 11·53) 3·76 (–0·30 to 7·83) 0·069
NPI carer distress subscore 78 11·5 (1·1) 84 10·2 (8·8) 1·37 (–1·45 to 4·19) 1·48 (–0·78 to 3·73) 0·199
12-week outcomes
Carer GHQ-12 44 13·1 (6·0) 52 12·2 (5·4) 0·88 (–1·43 to 3·19) 0·36 (–1·58 to 2·31) 0·714
Carer EQ-5D 46 0·80 (0·16) 49 0·82 (0·19) –0·02 (–0·09 to 0·06) 0·02 (–0·04 to 0·07) 0·561
Zarit Carer Burden Inventory† 42 35·5 (17·2) 48 29·0 (15·8) 6·48 (–0·43 to 13·39) 5·01 (0·80 to 9·23) 0·020
NPI carer distress subscore 72 10·0 (8·6) 81 10·5 (8·3) –0·52 (–3·22 to 2·17) –0·27 (–2·34 to 1·80) 0·798
CMAI=Cohen-Mansfield Agitation Inventory. GHQ-12=12-item General Health Questionnaire. NPI=neuropsychiatric inventory. *Adjusted for prespecified factors: baseline 
CMAI, household status, and centre. †Asked of family carers only.






End of week 4 91 97
3 study medications per day 50 (55%) 59 (61%)
2 study medications per day 11 (12%) 16 (16%)
1 study medication per day 9 (10%) 8 (8%)
0 study medications per day* 19 (21%) 14 (14%)
Dose information missing or 
inconsistent
2 (2%) 0
End of week 6 86 95
3 study medications per day 48 (56%) 49 (52%)
2 study medications per day 10 (12%) 23 (24%)
1 study medications per day 9 (10%) 8 (8%)
0 study medications per day* 13 (15%) 7 (7%)
Dose information missing or 
inconsistent
1 (1%) 8 (8%)
Compliance with study medication
In trial at 6 weeks 86 95
Compliance, mean percentage 
(SD)†
85 (16) 84 (16)
Compliance missing or 
inconsistent
44 (51%) 49 (52%)
In trial at 12 weeks 82 88
Taking trial medication at 
12 weeks
68 (83%) 76 (86%)
Compliance, mean percentage 
(SD)†
75 (23) 74 (27)
Compliance missing or 
inconsistent
49 (60%) 50 (57%)
Data are n, n (%), or mean (SD). *Combining those reported on 0 tablets a day and 
those choosing or advised to stop. †Compliance: number of tablets taken or 
expected number of tablets taken x 100, with number of tablets taken being 
based on expected number of tablets, minus number of tablets returned at 
6-week or 12-week visit; expected number of tablets calculated using prescribed 
number of tablets at each stage of the trial.
Table 4: Dose escalation and compliance with study medication
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for Regulatory Activities) terms showed no consistent 
pattern with the one death in the placebo group attributed 
to dementia, and the seven in the mirtazapine group 
attributed to (1) dementia; (2) pneumonia, aspiration; 
(3) emphysema, dementia, pneumonia, aspiration; 
(4) dementia, Alzheimer’s type; (5) cardiac failure; 
(6) pelvic fracture, osteoporosis, vascular dementia; and 
(7) chronic kidney disease, dementia, congestive cardiac 
failure.
Discussion 
This study is a trial with negative findings, but these 
findings have important clinical implications for practice. 
Our results indicate that mirtazapine, given with normal 
clinical care, is not clinically effective compared with 
placebo for the treatment of clinically significant agitation 
in people with dementia. This finding implies a need 
to change the present practice of prescription of 
mirtazapine, and possibly other sedative antidepressants, 
for agitation in dementia. In this study, there were clear 
decreases in agitation scores overall, with a clinically and 
statistically significant 10­point drop in the first 6 weeks 
of treatment, which was then maintained from 6 to 
12 weeks; however, this drop was not attributable to 
mirtazapine because it was also seen in the placebo 
group. It is concerning that although the total number of 
adverse events did not differ between the groups, 
mortality did differ, with seven deaths in the mirtazapine 
group compared with one in the placebo group. Although 
we do not know whether the deaths were related to 
mirtazapine, in the absence of clinical benefit attributable 
to mirtazapine, these potential harms mean that 
mirtazapine cannot be recommended for the treatment 
of agitation in dementia.
Our study has important potential limitations. First, 
there was a major adjustment to the initial trial protocol. 
We dropped the proposed carbamazepine group from the 
trial in response to slower­than­anticipated recruitment, 
which means we are unable to test hypotheses concerning 
the clinical effectiveness of carbamazepine in the 
treatment of agitation in dementia. Stopping recruitment 
to this group did not affect our ability to compare the 
clinical effectiveness of mirtazapine with placebo. 
However, the data from this trial only apply to mirtazapine 
and it is possible that other antidepressants from other 
classes might have a different effect; in the CitAD trial,17 
citalopram, a selective serotonin reuptake inhibitor, was 
reported to have had a modest positive effect, although 
with concerning adverse effects.
Second, the difference in mortality observed might 
have been by chance. This study was not powered to 
investigate a mortality difference between the groups. 
The analysis was post­hoc and its statistical significance 
marginal; in our previous study of depression in 
dementia, there were no more deaths in 108 participants 
randomly allocated to mirtazapine than in 111 participants 
randomly allocated to placebo.24 We therefore need to be 
careful in the interpretation of the mortality data in this 
study. Third, recruitment beyond February, 2020, was 
constrained by health research restrictions secondary to 
the COVID­19 pandemic. We only recruited 204 (92%) 
participants of the targeted 222 participants, but the 
closeness of the findings in both groups makes it highly 
unlikely that the results we found would have been 
different had there been another 18 participants randomly 
allocated to the groups as planned.
Finally, there are potential limitations in generalisability 
because we recruited most participants from old­age 
psychiatry services and care homes; outcomes might 
have been different in those living in the community 
treated by primary care services alone. However, in the 
UK, those with substantial agitation at home are likely to 
be referred to psychiatric services and would represent 
those for whom drug treatment might be indicated. In 
terms of generalisability, participants were not drawn 
only from specialist research clinics or tertiary care, but 
from 26 geographically diverse areas with a correspond­
ingly high number of clinicians who therefore are likely 
to cover the range of services in general. SYMBAD was 
designed to match real clinical populations and 
interventions closely. We kept exclusion criteria to a 
minimum and had permissive inclusion criteria, but the 
findings will not apply to individuals who are too critically 
ill to risk random allocation (such as those with high risk 
of harm to themselves or others). Only two potential 
participants were excluded for this reason, but there were 
probably others who were not referred to the trial.
The three main strengths of our study were high 
follow­up and compliance rates, the large sample size, 
and the broad nature of the study group (in terms of 
severity of agitation and severity and type of dementia). 
We were able to follow up 81 (79%) of the 102 participants 
in the mirtazapine group and 90 (88%) of the 
102 participants in the placebo group at 12 weeks, and 
complete primary outcome assessment. Our data suggest 
that over half of the participants in each group reached 
the target dose of medication and that compliance was 
high at over 80% at 6 weeks and over 70% at 12 weeks. 
However, our pragmatic trial design of effectiveness, 
with primary analyses and inference on an intention­to­
treat basis, and the relatively high level of missing data 
on compliance, limits any post­hoc analysis of outcome 
by compliance. Dropouts might have introduced bias if 
those not followed up had a different response to 
mirtazapine or placebo than those completing the trial. 
However, our rates of follow­up were relatively high, and 
the difference between the groups seems attributable to 
the six additional deaths in the mirtazapine group 
compared with placebo. We included individuals with 
probable and possible Alzheimer’s disease, not just 
narrowly defined Alzheimer’s disease; this inclusion is 
important because agitation can affect dementia of all 
causes and most people with dementia have mixed 
aetiology. Participants were therefore close to populations 
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encountered in clinical practice, in which there is often 
mixed dementia. However, our inclusion criteria mean 
that we should restrict generalisation of our findings to 
Alzheimer’s disease and mixed dementia and be cautious 
in applying them to other subtypes (eg, vascular, Lewy 
body, or frontotemporal dementia).
The US National Health and Nutrition Examination 
Survey showed that the highest rates of antidepressant 
use between 2015 and 2018 were in people aged over 60, 
of whom 19·0% were prescribed such medication.29 
Mirtazapine is commonly prescribed for older adults. In 
a study of people living in long­term care facilities in 
Helsinki, Finland, there was a marked increase in use of 
mirtazapine between 2003 and 2017: from 15·7% 
to 22·7% in nursing homes and from 14·0% to 23·8% in 
assisted living facilities, both settings with high 
prevalence of residents with dementia.30 In the MEDALZ 
cohort of 70 718 community­dwelling people with 
Alzheimer’s disease in Europe, mirtazapine was 
responsible for most new prescriptions (6462 [39·2%] of 
16 501 prescriptions).31 One reason for high rates of 
prescription of mirtazapine in later life is to avoid the use 
of antipsychotics.32 The influential NICE dementia 
guideline for the management of dementia is clear that 
antipsychotics should only be used in “agitation, 
aggression, distress and psychosis” when the person 
with dementia is at risk of harming themselves or others 
or where the agitation or psychosis is causing the person 
with dementia severe distress.19 The only other 
medication advice is that valproate should not be offered; 
there is no mention of antidepressants.
This absence of guidance on the use of alternative 
medications for agitation in all but the most extreme 
clinical situations means that clinicians will consider 
other medications. Sedative antidepressants such as 
mirtazapine, with which they are familiar, might appear 
an attractive and safe alternative to proscribed 
antipsychotics. However, there are reports that this might 
not be the case. Analyses of a primary care cohort showed 
increased all­cause mortality in people aged 20–64 who 
were prescribed mirtazapine.33 Taken together, the 
reports of potentially serious adverse effects of citalopram 
in the CitAD trial,17,18 of increased falls in trials of mixed 
dextromethorphan and quinidine,34 and of potentially 
higher mortality in the mirtazapine than the placebo 
group in this trial, present growing evidence that 
substituting antidepressants, or other novel compounds, 
for antipsychotics for the treatment of agitation in 
dementia is not a safe alternative.
In terms of secondary outcomes, the absence of any 
positive effects on participant and carer quality of life, on 
participant cognition, or on broader neuropsychiatric 
symptoms as measured by the NPI is striking. The 
potential positive effects for people with agitation in 
dementia and for their family carers observed in 
secondary analyses of our HTA­SADD study25 of people 
with depression in dementia were not found in this 
definitive study of people with agitation in dementia. Our 
study provides strong evidence that the overall 
improvement seen over the 12 weeks of the study is not 
attributable to mirtazapine, but SYMBAD cannot tell us 
what has caused it. The improvement might be a function 
of the potential therapeutic value of the non­drug 
treatment­as­usual provided by old­age psychiatric and 
primary care services, or it could be part of the natural 
course of agitation in dementia where symptoms can 
come and go. The latter is perhaps less probable given 
the observed persistence of agitation.7,35 It might also be 
due to artifacts such as regression to the mean, a placebo 
effect, or the Hawthorne effect, although the magnitude 
of the effect means that these artifacts are unlikely to be 
the whole reason for the changes observed.
In current systems, the data therefore suggest that 
waiting for a 6­week period (by which the improvement 
was noted), with reassessment afterwards, might be a 
reasonable and safe course of action for agitation in 
dementia. A policy of such active monitoring without the 
prescription of medication is recommended in the NICE 
guideline for depression as part of its stepped care model 
for the treatment of depression.36 As with our earlier 
study of the treatment of depression in dementia 
(HTA­SADD),24 our data suggest that finding agitation in 
dementia could be an appropriate trigger for referral 
to specialist services in which detailed assessment 
can be completed and non­drug treatments and 
active monitoring done, perhaps avoiding the use of 
medication.
Overall, this study adds to the evidence base that shows 
pharmacological interventions for agitation in dementia 
are limited in their effectiveness37,38 and associated with 
risk of harm. An important limitation in trials of drug and 
non­drug interventions for agitation is that the causes of 
agitation are heterogeneous and multifactorial. The 
syndrome might be caused by any combination of reasons 
as varied as: unmet needs (eg, hunger, thirst, pain), 
medical episodes (eg, infections, hypothyroidism), 
prescribed medication (eg, anticholinergics, steroids), and 
the environment (overstimulation or under stimulation), 
as well as the illness causing dementia. Even with initial 
investigation of the causes of the agitation and treatment 
with non­drug management as in this trial, any one­size­
fits­all intervention (whether a drug or non­drug 
intervention) for a heterogeneous syndrome such as 
agitation will have a high likelihood of failure due to lack 
of specificity. The fundamental presumption that there is 
a single neurobiological basis for agitation and therefore a 
specific drug that will target it, even in people with 
narrowly defined Alzheimer’s disease or those with closely 
defined symptom clusters, seems particularly weak. 
Drugs for which a signal of effect has been found, such as 
risperidone and citalopram, appear to have achieved those 
effects through general sedative side­effects, which also 
drive much of the harm from such medication in the frail 
population with dementia.
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We need to challenge the dominant, simple target­
based framework for the development and testing of 
interventions for complex challenges such as agitation in 
dementia. Approaches that are inclusive of the 
heterogeneity of causation and tailor an individualised 
programme of investigation and management including 
social and psychological as well as pharmacological 
interventions could be of greater value. The implications 
of this study are not just that mirtazapine does not work 
and is potentially harmful. There are also reasons to be 
positive that treatment­as­usual by current primary and 
secondary health­care services could well enable people 
with agitation and dementia to recover from that agitation 
without the use of medication and its potential harms.
Contributors
SB was the chief investigator for the study and designed and managed 
the study with input from all other authors. SS and LS did the statistical 
analyses. All authors participated in data interpretation. JH, SS, LS, CH, 
and SB verified the underlying data. SB drafted the first and subsequent 
versions of this paper with input and key revisions by all authors, who 
reviewed and approved the final submitted paper. All authors had full 
access to all the data in the study and had final responsibility for the 
decision to submit for publication.
SYMBAD Recruitment group 
Trial Investigators: Barnet Elizabeth Sampson, Belfast 
Bernadette McGuinness, Bournemouth Divya Tiwari, Bradford 
Sushanth Kamath, Gregor Russell, Cambridgeshire Catherine Hatfield, 
Central and NW London Erum Nomani, Coventry Demi Onalaja, Dudley 
Udaya Balakrishna, Exeter Carol Bannister, Joseph Butchart, 
Simona Brown, Gateshead Karen Franks, Kings College Adenike Dare, 
Leicester Matthew Critchfield, Matthew Noble, Manchester Ross Dunne, 
Midlands Rashi Negi, Norfolk Heather Cooke, Northamptonshire 
Paul Koranteng, Rotherham Oluwafemi Adio, Sheffield Aparna Mordekar, 
SW London Robert Lawrence, SW Yorkshire Suba Thiyagesh, Surrey 
Gareth O’Leary, Sussex Andrew Risbridger, Gosia Raczek, Richard Hoile, 
Worcestershire Dhanjeev Marrie, 2Gether Emma Abbey. Research Nurses, 
Research Workers and Clinical Research Network Staff: 
Barnet Luiza Grycuk, Tom Freeth Birmingham Analisa Smythe, 
Di Baines, Jan Wright, Jane Dyer, Bradford Jason Cook, Sarah Kirkland, 
Zarina Mirza, Cambridgeshire Windsor Research Unit 
Julie Philps Naomi Thomas, Marina Bishop, Siobhan Coleman, 
Gloria Calderon, Central and NW London Desiree Fyle, Coventry 
Emily Benson, Dudley Aurora Balalia, Exeter Amanda Henderson, 
Anna Grice, Olga Borejko, Sarah Brown, Stacey Horne, Sue Dyson, 
Gateshead Bryony Storey, Elaine Siddle, Kings College Shaula Candido, 
Leicester Iain Termie, Sarah Ballion, Manchester Dee Leonard, 
Lewis Harpin, Phillip Tinkler, Rebecca Davies, Selina Sonola, Midlands 
Paula Coventry, Susan Lavendar, Norfolk Caroline Sheldon, 
Claire Rischmiller, Kim Clipsham, Zoe Inman, Northamptonshire 
Chetan Lakhani, North London Liam Pikett, Narin Aker, Rotherham 
Helen Oldknow, Sheffield Hannah Gower, SW London Na’ilah Firdaws, 
Surrey George Shaya, Jessica True, Mariana Gavrilla, Sally Gosling, 
Sussex Angela Ozduran, Elise Armsby, Keren Teichmann, 
Marcela Carvajal, Natalie Portwine, Rachel Russell, Sam Holden, 
Sharne Berwald, Tamsin Eperson, 2Gether Marelle Harvey, Sarah Little. 
Norwich Clinical Trials Unit staff Erika Sims, Estelle Payerne, 
Hazel Hobbs, Katharine Goodall, Lee Kitchman, Matt Hammond, 
Megan Jones, Nick Leavey, Veronica Bion.
Declaration of interests
SB reports personal fees and non­financial support from Lilly; personal 
fees from Boehringer­Ingelheim, Axovant, Lundbeck, and Nutricia; 
and honoraria from the Hamad Medical Service for lectures and talks; 
outside the submitted work. He is a Trustee of the Alzheimer’s Society 
and has research grants from UK National Institute for Health Research 
(NIHR), Economic and Social Research Council, and Engineering and 
Physical Sciences Research Council. AB reports being National Clinical 
Director for Dementia at NHS England and receiving professional fees 
from NHS England, personal fees from International Journal of 
Geriatric Psychiatry, personal fees from lectures and talks and from 
medico­legal reports and the Driver and Vehicle Licensing Authority, 
outside the submitted work. CB reports grants and personal fees from 
Acadia, Lundbeck; personal fees from Roche, Otsuka, Novartis, Eli Lilly, 
Suven, Sunovion, ADDEX, and Exciva; personal fees and travel expenses 
from Synexus, Novo Nordisk; and travel expenses from Biogen; outside 
the submitted work. PB reports work as a paid consultant for TauRx 
Therapeutics outside the submitted work. RH reports grant support 
from NIHR and being a Trustee of Alzheimer’s Research UK. JO reports 
personal fees from TauRX Therapeutics, Axon, GE Healthcare, Roche, 
and Eisai; non­financial support from Alliance Medical; and grants from 
Merck; outside the submitted work. NT reports grant support from 
Avenir Pharma and NIHR Applied Research Collaborations and 
Comprehensive Research Network leadership roles. AJT reports grants 
from the NIHR Health Technology Assessment Programme, during the 
conduct of the study. All other authors declare no competing interests 
other than NIHR funding for investigator time on this grant.
Data sharing
Deidentified participant data will be available with investigator support 
from 9 months after publication of the final project reports via 
sube.banerjee@plymouth.ac.uk by researchers whose proposed use of 
the data has been approved by the Trial Management Committee for 
meta­analyses or analyses that have been approved. The trial protocol 
can be found in the appendix p 3).
Acknowledgments
This project was funded by the UK National Institute for Health 
Research (NIHR) Health Technology Assessment (HTA) programme 
(project number 13/115/76). The views and opinions expressed here 
are those of the authors and do not necessarily reflect those of the 
HTA programme, NIHR, National Health Service, or the Department 
of Health and Social Care. We thank all the participants and carers that 
gave their time to be part of this study; Antony Colles, Martin Pond, 
and the Norwich Clinical Trials Unit data management team for 
database design and expertise; members of the SYMBAD Data 
Monitoring Committee and Trial Steering Committee (Bart Sheehan 
[chair Data Monitoring Committee], Peter Connelly [chair Trial 
Steering Committee], Adrian Treloar, Siobhan Creanor, Toby Prevost, 
Andy Barker, Chris Penrose, and Julie West); Julia Fountain and our 
Lived Experience Advisory Panel; the Alzheimer’s Society for providing 
patient and public involvement support into the study; the NIHR 
Clinical Research Network Dementia specialty for help in recruitment; 
Join Dementia Research registry team; Antony Walsh and the 
sponsorship and grant management teams at the University of Sussex; 
and referring clinicians in every area. SB is supported as an NIHR 
Senior Investigator. RH is supported by the UCLH/UCL Biomedical 
Research Centre. GL is supported by the UCLH/UCL Biomedical 
Research Centre, North Thames NIHR Applied Research 
Collaboration, and as an NIHR Senior Investigator. AJT is supported 
by Newcastle NIHR Biomedical Research Centre and Brains for 
Dementia Research. JO is supported by the Cambridge NIHR 
Biomedical Research Centre.
References
1 Livingston G, Sommerlad A, Orgeta V, et al. Dementia prevention, 
intervention, and care. Lancet 2017; 390: 2673–734.
2 Prince M, Wimo A, Guerchet M, Ali G­C, Wu Y­T, Prina M. 
World Alzheimer Report 2015. The global impact of dementia. 
An analysis of prevalence, incidence, cost and trends. 
London: Alzheimer’s Disease International, 2015.
3 Savva GM, Zaccai J, Matthews FE, Davidson JE, McKeith I, 
Brayne C. Prevalence, correlates and course of behavioural and 
psychological symptoms of dementia in the population. 
Br J Psychiatry 2009; 194: 212–19.
4 van der Linde RM, Dening T, Stephan BC, Prina AM, Evans E, 
Brayne C. Longitudinal course of behavioural and psychological 
symptoms of dementia: systematic review. Br J Psychiatry 2016; 
209: 366–77.
5 Cohen­Mansfield J, Billing N. Agitated behaviors in the elderly: 
I. A conceptual review. J Am Geriatrics Soc 1986: 34: 711–21.
Articles
www.thelancet.com   Vol 398   October 23, 2021 1497
6 Okura T, Plassman BL, Steffens DC, Llewellyn DJ, Potter GG, 
Langa KM. Prevalence of neuropsychiatric symptoms and their 
association with functional limitations in older adults in the 
United States: the aging, demographics, and memory study. 
J Am Geriatr Soc 2010; 58: 330–37.
7 Ryu S­H, Katona C, Rive B, Livingston G. Persistence of and 
changes in neuropsychiatric symptoms in Alzheimer disease over 
6 months: the LASER­AD study. Am J Geriatr Psychiatry 2005; 
13: 976–83.
8 Wetzels RB, Zuidema SU, de Jonghe JFM, Verhey FRJ, 
Koopmans RTCM. Course of neuropsychiatric symptoms in 
residents with dementia in nursing homes over 2­year period. 
Am J Geriatr Psychiatry 2010; 18: 1054–65.
9 Kales HC, Gitlin LN, Lyketsos CG. Assessment and management of 
behavioral and psychological symptoms of dementia. BMJ 2015; 
350: h369.
10 Rabins PV, Rovner BW, Rummans T, Schneider LS, Tariot PN. 
Guideline Watch (October 2014): practice guideline for the 
treatment of patients with Alzheimer’s disease and other 
dementias. 2014. http://psychiatryonline.org/pb/assets/raw/
sitewide/practice_guidelines/guidelines/alzheimerwatch.pdf 
(accessed Nov 15, 2020).
11 Banerjee S. The use of antipsychotic medication for people with 
dementia: time for action. A report. 2009. https://webarchive.
nationalarchives.gov.uk/20121030234317/http://www.dh.gov.uk/en/
Publicationsandstatistics/Publications/Publications 
PolicyAndGuidance/DH_108303 (accessed Feb 15, 2021).
12 Donegan K, Fox N, Black N, Livingston G, Banerjee S, Burns A. 
Trends in diagnosis and treatment for people with dementia in the 
UK from 2005 to 2015: a longitudinal retrospective cohort study. 
Lancet Public Health 2017; 2: e149–56.
13 Howard RJ, Juszczak E, Ballard CG, et al. Donepezil for the 
treatment of agitation in Alzheimer’s disease. N Engl J Med 2007; 
357: 1382–92.
14 Fox C, Crugel M, Maidment I, et al. Efficacy of memantine for 
agitation in Alzheimer’s dementia: a randomised double­blind 
placebo controlled trial. PLoS One 2012; 7: e35185.
15 Tariot PN, Schneider LS, Cummings J, et al. Chronic divalproex 
sodium to attenuate agitation and clinical progression of Alzheimer 
disease. Arch Gen Psychiatry 2011; 68: 853–61.
16 Defrancesco M, Marksteiner J, Fleischhacker WW, Blasko I. Use of 
benzodiazepines in Alzheimer’s disease: a systematic review of 
literature. Int J Neuropsychopharmacol 2015; 18: pyv055.
17 Porsteinsson AP, Drye LT, Pollock BG, et al. Effect of citalopram on 
agitation in Alzheimer disease: the CitAD randomized clinical trial. 
JAMA 2014; 311: 682–91.
18 Schneider LS, Frangakis C, Drye LT, et al. Heterogeneity of 
treatment response to citalopram for patients with Alzheimer’s 
disease with aggression or agitation: the CitAD randomized clinical 
trial. Am J Psychiatry 2016; 173: 465–72.
19 UK National Institute for Health and Care Excellence. Dementia: 
assessment, management and support for people living with 
dementia and their carers. London: National Institute of Health and 
Care Excellence, 2018.
20 Maust DT, Kim HM, Chiang C, Kales HC. Association of the 
Centers for Medicare & Medicaid Services’ national partnership to 
improve dementia care with the use of antipsychotics and other 
psychotropics in long­term care in the United States from 
2009 to 2014. JAMA Intern Med 2018; 178: 640–47.
21 Gerlach LB, Kales HC, Kim HM, et al. Trends in antipsychotic and 
mood stabilizer prescribing in long­term care in the US: 2011–2014. 
J Am Med Dir Assoc 2020; 21: 1629–1635.e8.
22 Maust DT, Strominger J, Kim HM, et al. Prevalence of central 
nervous system­active polypharmacy among older adults with 
dementia in the US. JAMA 2021; 325: 952–61.
23 Forns J, Pottegård A, Reinders T, et al. Antidepressant use in 
Denmark, Germany, Spain, and Sweden between 2009 and 2014: 
incidence and comorbidities of antidepressant initiators. 
J Affect Disord 2019; 249: 242–52.
24 Banerjee S, Hellier J, Dewey M, et al. Sertraline or mirtazapine for 
depression in dementia (HTA­SADD): a randomised, multicentre, 
double­blind, placebo­controlled trial. Lancet 2011; 378: 403–11.
25 Romeo R, Knapp M, Hellier J, et al. Cost­effectiveness analyses for 
mirtazapine and sertraline in dementia: randomised controlled 
trial. Br J Psychiatry 2013; 202: 121–28.
26 McKhann G, Drachman D, Folstein M, Katzman R, Price D, 
Stadlan EM. Clinical diagnosis of Alzheimer’s disease: report of the 
NINCDS­ADRDA Work Group. Neurology 1984; 34: 939–44.
27 Cohen­Mansfield J. Conceptualization of agitation: results based on 
the Cohen­Mansfield Agitation Inventory and the Agitation 
Behavior Mapping Instrument. Int Psychogeriatr 1996; 
8 (suppl 3): 309–15.
28 Alzheimer’s Society. Optimising treatment and care for people with 
behavioural and psychological symptoms of dementia: a best 
practice guide for health and social care professionals. London: 
Alzheimer’s Society, 2011.
29 Brody DJ, Gu Q. Antidepressant use among adults: United States, 
2015–2018. NCHS Data Brief 2020; 377: 1–8.
30 Aalto UL, Roitto HM, Finne­Soveri H, Kautiainen H, Pitkälä KH. 
Temporal trends in the use of anticholinergic drugs among older 
people living in long­term care facilities in Helsinki. Drugs Aging 
2020; 37: 27–34.
31 Kettunen R, Taipale H, Tolppanen AM, et al. Duration of new 
antidepressant use and factors associated with discontinuation 
among community­dwelling persons with Alzheimer’s disease. 
Eur J Clin Pharmacol 2019; 75: 417–25.
32 Marcinkowska M, Śniecikowska J, Fajkis N, Paśko P, Franczyk W, 
Kołaczkowski M. Management of dementia­related psychosis, 
agitation and aggression: a review of the pharmacology and clinical 
effects of potential drug candidates. CNS Drugs 2020; 34: 243–68.
33 Coupland C, Hill T, Morriss R, Moore M, Arthur A, Hippisley­Cox J. 
Antidepressant use and risk of adverse outcomes in people aged 
20­64 years: cohort study using a primary care database. BMC Med 
2018; 16: 36.
34 Cummings JL, Lyketsos CG, Peskind ER, et al. Effect of 
dextromethorphan­quinidine on agitation in patients with 
Alzheimer disease dementia: a randomized clinical trial. JAMA 
2015; 314: 1242–54. .
35 Marston L, Livingston G, Laybourne A, Cooper C. Becoming or 
remaining agitated: the course of agitation in people with dementia 
living in care homes. The English Longitudinal Managing Agitation 
and Raising Quality of Life (MARQUE) Study. J Alzheimers Dis 
2020; 76: 467–73.
36 UK National Collaborating Centre for Mental Health. Depression: 
the treatment and management of depression in adults (updated 
edition). National clinical practice guideline 90. London, UK: 
The British Psychological Society and The Royal College of 
Psychiatrists, 2020.
37 Kongpakwattana K, Sawangjit R, Tawankanjanachot I, Bell JS, 
Hilmer SN, Chaiyakunapruk N. Pharmacological treatments for 
alleviating agitation in dementia: a systematic review and network 
meta­analysis. Br J Clin Pharmacol 2018; 84: 1445–56.
38 Watt JA, Goodarzi Z, Veroniki AA, et al. Comparative efficacy of 
interventions for aggressive and agitated behaviors in dementia: 
a systematic review and network meta­analysis. Ann Intern Med 
2019; 171: 633–42.
39 Grossberg GT, Kohegyi E, Mergel V, et al. Efficacy and safety 
of brexpiprazole for the treatment of agitation in Alzheimer’s 
dementia: two 12­week, randomized, double­blind, placebo­controlled 
trials. Am J Geriatr Psychiatry 2020; 28: 383–400.
